Shlomo Flechter

TL;DR: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with MS should be vaccinated against COVID-19 as discussed by the authors, however, they did not recommend that all MS patients with mild relapses be vaccinated.

TL;DR: The predominant response to MOG of PBL from MS patients as demonstrated in two separate studies using native MOG and rhMOG as antigens, and the high incidence of reactivity of these PBL compared to the lack of response to phMOG by control PBL, emphasize the relevance of MOG in MS pathogenesis and support a primary role for the autoimmune T cell response toMOG in disease development.

TL;DR: In this article, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed, since vaccination against coronavirus disease 2019 (COVID-19) became available.

TL;DR: Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and primary progressive multiple sclerosis, finding decline in relapse activity over time is more closely related to patient age than disease duration.

TL;DR: It is concluded that demographic, clinical and paraclinical information helps predict individual response to disease‐modifying therapies at the time of their commencement, and high external validity for disability and relapse outcomes and low external validityfor conversion to secondary progressive disease and treatment discontinuation.